ClinicalTrials.gg
RecruitingNCT06262581Updated Feb 16, 2024

Neoadjuvant Tisleizumab(BGB-A317) for dMMR/MSI-H Non-late Stage CRC Patients Before Surgery

A Phase 2 interventional study of Tisleizumab(BGB-A317) in DMMR Colorectal Cancer, Anti PD-1 and Immunotherapy, sponsored by Sun Yat-sen University. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-16.

Sponsored by Sun Yat-sen University · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Started Sep 2023; still recruiting 3 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies testing tislelizumab in Colorectal Neoplasms — 15 open to participants now, 19 under way, 1 of them phase 3. tislelizumab · Colorectal Neoplasms.

Planned enrollment
9th of 27
40 · median 33
Started
2023
with 7 others
Phase 2
20 of 27
10 open now
Primary completion
2024-11
later than 1 of 18 live
Registered
12th of 27
by date
Lead sponsor
3 of 27
Sun Yat-sen University

Among the 27 studies testing tislelizumab in Colorectal Neoplasms, this one is the 9th largest by planned enrollment, is one of 8 that started in 2023, is one of 20 in phase 2, reaches primary completion later than 1 of the 18 other live ones, and was the 12th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

15 of the 27 studies testing tislelizumab in Colorectal Neoplasms are open now, in 5 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About tislelizumab

tislelizumab: first FDA approval 2024 (TEVIMBRA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing tislelizumab in Colorectal Neoplasms, or all of them as a file.
02

Study summary

According to the cancer statistics in 2020, colorectal cancer (CRC) remains a major public health issue worldwide, representing the third common cancer (10%) and second leading cause of death (9.4%) with 5-year survival rate approaching 65%. Meanwhile, 28.8% of the newly diagnosed cases and 30.3% of the CRC-related death occurs in China. Among all the CRC, stage I-III account for 75%. For the standard management for non-late stage(stage I-III) CRC patients, surgery including the primary site and local lymph nodes dissection has been the most important one. But for the high-risk stage II and locally-advanced stage III CRC, neoadjuvant or adjuvant therapy such as chemotherapy and radiotherapy plays a vital role in preventing the residual cancer cells to relapse and spread to distant sites after surgery. For the past decades, immunotherapy like anti-PD-1 and anti-CTLA4 checkpoint inhibitor achieves great process in solid tumor treatment especially for late-stage CRC. And Pembrolizumab and Nivolumab has been proved for dMMR/MSI-H late-stage-CRC by FDA. Combination of Ipilimumab and Nivolumab has achieved great success among the early-stage-CRC in NICHE study. The investigators here to carry out a phase II clinical trial to explore the safety and effect of single anti-PD-1 (Tisleizumab-BGB-A317 ) neoadjuvant treatment for non-late stage CRC patients.

03

Conditions studied

  • DMMR Colorectal Cancer
  • Anti PD-1
  • Immunotherapy

Keywords

  • CRC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able to provide consents and agree to follow the trial requirement and assessment;
  • Age >=18
  • score: 0 or1
  • pathological diagnosis as MSI-H/dMMR( both IHC and PCR method required)
  • Measurable and assessible primary tumor sites according to 1.1
  • Able to provide 22ml peripheral blood for assessment for ctDNA
  • With all organ function sufficient
  • No bowel obstruction or fistula
  • No previous chemotherapy, radiotherapy and immunotherapy accepted history
  • Distant excluded before surgery by CT scan
  • required for women for the whole enrollment time until 3 months after last dose of immunotherapy

Exclusion criteria

Exclusion Criteria:

  • self- diseases history such as SLE
  • People who using the immune suppressor
  • Severe allergy to other mono-clone antibody
  • Cerebral which hasn't be managed yet
  • Hypertension(SBP>140mmHg,DBP>90mmHg)
  • Uncontrolled diabetes(FBG>10mmol/L)
  • Accepted or anti-PD-L1 immunotherapy in the past
  • Uncontrolled heart diseases such as II heart failure, unstable angina , cardiac infarction in 1 year and arrhythmia
  • Systemic inflammation which needs whole body treatment
  • Urine routine: protein >=++ or 24hr urine protein>=1g
  • Innate or acquired immune deficiency like and
  • Enrolled in other clinical trial already
  • Confirmed as metastasis before the surgery
  • Other has been diagnosed before
  • Tuberculosis
  • Pregnancy
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    dMMR/MSI-H stage I-III CRC patients

    Patients will accept 4 dose of Tisleizumab(BGB-A317) treatment after enrollment and the assessment of the therapeutic effect by clinicians would be finished after that. Once the patients has been qualified as cCR , they could be exempted for surgery and continued the watch and wait management. If the patient has been assessed as able to R0 surgery , then they would received surgery. Otherwise ,they would be excluded from the trial.

    Drug: Tisleizumab(BGB-A317)

Interventions

06

What researchers measure

Primary outcomes

  1. pathological complete regression rate

    Patients without noninvasive or focal-invasive residues or involved lymph nodes should be considered as having achieved pCR. The rate is these patients over the whole group.

    Time frame: From enrollment to 1 year after surgery

Secondary outcomes

  1. CR rate

    Patients with non-invasive or focal-invasive or involved lymph nodes which persists for 4 weeks after neoadjuvant immunotherapy. The rate of these patients over the whole group.

    Time frame: From enrollment to 1 year after surgery

  2. Major Pathological Response rate

    Rate of the patients who had focal invasive and residue tumor site which less than 10% both in primary tumors and all lymph nodes.

    Time frame: From enrollment to 1 year after surgery

  3. Disease free survival

    The time interval between the enrollment to the events such as relapse, distant metastasis and progressed occured.

    Time frame: From enrollment to 1 year after surgery

07

Study locations

1 of 1 sites recruiting
  • Sun Yat-Sen University Cancer Center
    Guangzhou, Guangdong 510060, China
    Recruiting
    • Gong C Chen, Prof · Contactchengong@sysucc.org.cn · +862087343584
    • Zhi-zhong Pan, Prof · Sub investigator
    • Xiao-jun Wu, Prof · Sub investigator
    • Zhen-hai Lu, Prof · Sub investigator
    • Pei-rong Ding, Prof · Sub investigator
    • Li-ren Li, Prof · Sub investigator
    • Fu-long Wang, M.D. · Sub investigator
    • Rong-xin Zhang, M.D. · Sub investigator
    • Jian-hong Peng, M.D. · Sub investigator
    • Jun-zhong Lin, M.D. · Sub investigator
    • Ling-heng Kong, M.D. · Sub investigator
    • Cong Li, M.D. · Sub investigator
    • Wu Jiang, M.D. · Sub investigator
    • Wen-hua Fan, M.D. · Sub investigator
    • Wen-hao Zhou, M.D. · Sub investigator
    • Jing-hua Tang, M.D. · Sub investigator
    • Yuan Li, M.D. · Sub investigator
    • Miaoqing Wu · Sub investigator
    • Di Cao · Sub investigator
    • Yi-fan Liu · Sub investigator
    • Da Kang · Sub investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Nov 2024, 14 months after the start.

Of 499 non-industry phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 75. This study's planned 14 months is below that.

Counting every sponsor, half of 619 studies reached it within 49 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2022
First posted
Feb 16, 2024
StartActual
Sep 23, 2023
Primary completionEst.
Nov 30, 2024
CompletionEst.
Dec 31, 2025
Last update
Feb 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06262581
Responsible party
Gong Chen (Professor, Sun Yat-sen University) — Principal investigator
First posted
Feb 16, 2024
Start date
Sep 23, 2023
Primary completion
Nov 30, 2024 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Feb 16, 2024

Study contacts

Gong Chen, Prof
Contact
chengong@sysucc.org.cn
+86 020 87343584
Rong-xin Zhang, Prof
Contact
zhangrx@sysucc.org.cn
+86 020 87343584
Gong Chen, Prof
principal investigator · Sun Yat-sen University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tislelizumab

Start the discussion